13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $781M | $63M | 59.3% | 23.0% | $328M | — | $231M |
| 2024 | $631M | $69M | 59.8% | 26.9% | $203M | — | $71M |
| 2023 | $567M | $48M | 57.5% | 29.5% | $274M | — | $239M |
| 2022 | $464M | -$25M | 45.2% | 7.2% | $123M | — | $174M |
| 2021 | $277M | $72M | 54.4% | 6.4% | $102M | — | $186M |
| 2020 | $310M | $27M | 58.0% | 18.1% | $88M | — | $174M |
| 2019 | $297M | -$23M | 34.7% | -8.0% | $21M | $12M | $170M |
| 2018 | $280M | -$39M | 40.9% | -7.4% | $164M | $12M | $147M |
| 2017 | $28M | -$75M | 90.9% | -264.9% | -$68M | — | $119M |
| 2016 | $2M | -$94M | 87.6% | -5498.7% | -$76M | $4M | $153M |
| 2015 | — | -$27M | — | — | -$22M | $7M | $96M |
| 2014 | — | -$18M | — | — | — | — | $2M |
| 2013 | — | -$16M | — | — | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $194M | $14M | 60.6% | 16.0% | $57M | — | $269M |
| Dec '25 | $205M | $17M | 62.5% | 29.6% | $122M | — | $231M |
| Sep '25 | $209M | $32M | 61.7% | 29.7% | $78M | — | $150M |
| Jun '25 | $188M | $12M | 57.7% | 18.7% | $72M | — | $117M |
| Mar '25 | $178M | $2M | 54.8% | 12.2% | $55M | — | $96M |
| Dec '24 | $182M | $13M | 54.0% | 20.9% | $84M | — | $71M |
| Sep '24 | $159M | $9M | 60.8% | 21.9% | -$9M | — | $39M |
| Jun '24 | $145M | $20M | 62.5% | 32.7% | $67M | — | $173M |
| Mar '24 | $145M | $28M | 63.1% | 34.1% | $61M | — | $229M |
| Dec '23 | $150M | $32M | 63.2% | 41.2% | $73M | — | $239M |
| Sep '23 | $137M | $21M | 58.7% | 32.9% | $74M | — | $259M |
| Jun '23 | $136M | $13M | 54.5% | 26.3% | $100M | — | $284M |
| Mar '23 | $145M | -$17M | 53.5% | 17.0% | $27M | — | $269M |
| Dec '22 | $130M | -$7M | 38.4% | 9.1% | $65M | — | $174M |
| Sep '22 | $127M | $457000 | 46.3% | 16.1% | $43M | — | $134M |
| Jun '22 | $124M | -$5M | 42.4% | 9.0% | $40M | — | $123M |
| Mar '22 | $84M | -$13M | 57.9% | -12.0% | -$25M | — | $107M |
| Dec '21 | $27M | -$25M | -4.9% | -124.7% | $36M | — | $186M |
| Sep '21 | $79M | $8M | 58.5% | 17.9% | $17M | — | $193M |
| Jun '21 | $83M | $73M | 60.6% | 19.8% | $29M | — | $203M |
How the market has priced COLL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Collegium Pharmaceutical, Inc's revenue has grown 20.3% per year, and net income grown 18.7% per year. These are computed facts, not advice.
As of FY2025, Collegium Pharmaceutical, Inc reported — of total debt against $231M of cash; operating income covered interest expense 2.2×.
In FY2025, gross margin was 59.3%, operating margin 23.0%, and net margin 8.1%.
As of Jun '26, Collegium Pharmaceutical, Inc traded at a price-to-earnings ratio of about 17.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.